[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research advances in stereotactic body radiation therapy for primary liver cancer
Tong Jinlong,Zheng Qin,Sun Xinchen
Department of Radiation Oncology,Affliated Second Hospital of Southeast University,Nanjing 210029,China (Tong JL,Zheng Q);Department of Radiation Oncology,First Hospital of Nanjing Medical University,Nanjing 210029,China (Sun XC)
Abstract Stereotactic body radiation therapy (SBRT) adopts different tumor-killing mechanisms from the conventional fractionated radiotherapy. In SBRT, a single high-dose radiation can destroy the membrane of tumor cells and induce the release of tumor-associated antigen, also named in situ tumor vaccine, which stimulates the immune system to kill the residual tumor;a single-fraction radiation with a dose larger than 8-10 Gy can induce rapid apoptosis of vascular endothelial cells via the acid sphingomyelinase pathway at 1-6 hours after radiation, which causes tumor vascular occlusion and secondary tumor-killing effects. In order to understand whether SBRT improves the clinical treatment outcomes via the above mechanisms, this paper reviews the clinical research advances in SBRT for primary liver cancer.
Corresponding Authors:
Sun Xinchen,Email:sunxch055@163.com
Cite this article:
Tong Jinlong,Zheng Qin,Sun Xinchen. Research advances in stereotactic body radiation therapy for primary liver cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(2): 234-238.
Tong Jinlong,Zheng Qin,Sun Xinchen. Research advances in stereotactic body radiation therapy for primary liver cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(2): 234-238.
[1] Song CW,Cho LC,Yuan JL,et al. Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model[J].Int J Radiat Oncol Biol Phys,2013,87(1):18-19.DOI:10.1016/j.ijrobp.2013.03.013. [2] Garcia-Barros M,Paris F,Cordon-Cardo C,et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis[J].Science,2003,300(5622):1155-1159.DOI:10.1126/science.1082504. [3] Kolesnick R,Fuks Z.Radiation and ceramide-induced apoptosis[J].Oncogene,2003,22(37):5897-5906.DOI:10.1038/sj.onc.1206702. [4] Park HJ,Griffin RJ,Hui S,et al. Radiation-induced vascular damage in tumors:implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)[J].Radiat Res,2012,177(3):311-327.DOI:10.1667/RR2773.1. [5] Cornelissen M,Thierens H,De Ridder L.Interphase death in human peripheral blood lymphocytes after moderate and high doses of low and high LET radiation:an electron microscopic approach[J].Anticancer Res,2002,22(1A):241-245. [6] Lee Y,Auh SL,Wang YG,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood, 2009,114(3):589-595.DOI:10.1182/blood-2009-02-206870. [7] Cárdenes HR,Price TR,Perkins SM,et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma[J].Clin Transl Oncol,2010,12(3):218-225.DOI:10.1007/s12094-010-0492-x. [8] Yoon SM,Lim YS,Park MJ,et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma[J].PLoS One,2013,8(11):e79854.DOI:10.1371/journal.pone.0079854. [9] Kwon JH,Bae SH,Kim JY,et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer[J].BMC Cancer,2010,10(1):475.DOI:10.1186/1471-2407-10-475. [10] Kimura T,Aikata H,Takahashi S,et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies[J].Hepatol Res,2015,45(4):378-386.DOI:10.1111/hepr.12359. [11] Scorsetti M,Comito T,Cozzi L,et al. The challenge of inoperable hepatocellular carcinoma (HCC):results of a single-institutional experience on stereotactic body radiation therapy (SBRT)[J].J Cancer Res Clin Oncol,2015,141(7):1301-1309.DOI:10.1007/s00432-015-1929-y. [12] Sanuki N,Takeda A,Oku Y,et al. Stereotactic body radiotherapy for small hepatocellular carcinoma:a retrospective outcome analysis in 185 patients[J].Acta Oncol,2014,53(3):399-404.DOI:10.3109/0284186X.2013.820342. [13] Andolino DL,Johnson CS,Maluccio M,et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2011,81(4):e447-e453.DOI:10.1016/j.ijrobp.2011.04.011. [14] Takeda A,Sanuki N,Eriguchi T,et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma[J].J Gastroenterol Hepatol,2014,29(2):372-379.DOI:10.1111/jgh.12350. [15] Honda Y,Kimura T,Aikata H,et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma[J].J Gastroenterol Hepatol,2013,28(3):530-536.DOI:10.1111/jgh.12087. [16] Park JH,Yoon SM,Lim YS,et al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma[J].J Gastroenterol Hepatol,2013,28(10):1638-1642.DOI:10.1111/jgh.12249. [17] Bae SH,Park HC,Lim DH,et al. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2012,82(4):e603-e607.DOI:10.1016/j.ijrobp.2011.09.053. [18] Yuan ZY,Tian LJ,Wang P,et al. Comparative research on the efficacy of CyberKnifeand surgical excision for Stage I hepatocellular carcinoma[J].Onco Targets Ther,2013,6:1527-1532.DOI:10.2147/OTT.S51452. [19] Seo YS,Kim MS,Yoo SY,et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma[J].J Surg Oncol,2010,102(3):209-214.DOI:10.1002/jso.21593. [20] Tse RV,Hawkins M,Lockwood G,et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J].J Clin Oncol,2008,26(4):657-664.DOI:10.1200/JCO.2007.14.3529. [21] Bujold A,Massey CA,Kim JJ,et al. Sequential phase I and Ⅱ trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J].J Clin Oncol,2013,31(13):1631-1639.DOI:10.1200/JCO.2012.44.1659. [22] Que JY,Lin LC,Lin KL,et al. The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities[J].Radiat Oncol,2014,9(1):120.DOI:10.1186/1748-717X-9-120. [23] Llovet JM,Ricci S,Mazzaferro V,et al. Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.DOI:10.1056/NEJMoa0708857. [24] Cheng AL,Kang YK,Chen ZD,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.DOI:10.1016/S1470-2045(08)70285-7. [25] Wahl DR,Stenmark MH,Tao YB,et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J].J Clin Oncol,2016,34(5):452-459.DOI:10.1200/JCO.2015.61.4925. [26] Choi BO,Choi IB,Jang HS,et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma:preliminary analysis[J].BMC Cancer,2008,8(1):351.DOI:10.1186/1471-2407-8-351. [27] Xi M,Zhang L,Zhao L,et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis[J].PLoS One,2013,8(5):e63864.DOI:10.1371/journal.pone.0063864. [28] 吴德华,陈龙华.低分割三维适形放疗结合介入治疗肝细胞癌伴门静脉癌栓的疗效[J].癌症,2004,23(7):825-828.DOI:10.3321/j.issn:1000-467X.2004.07.018. Wu DH,Chen LH.Efficacy of 3 dimensional conformal hypofractionated single high dose radiotherapy combined with transcatheter arterial chemoembolization for portal vein tumor thrombus in patients with hepatocellular carcinoma[J].Chin J Cancer, 2004,23(7):825-828. DOI:10.3321/j.issn:1000-467X.2004.07.018. [29] Culleton S,Jiang HY,Haddad CR,et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma[J].Radiother Oncol,2014,111(3):412-417.DOI:10.1016/j.radonc.2014.05.002. [30] Jung J,Yoon SM,Kim SY,et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma:clinical and dose-volumetric parameters[J].Radiat Oncol, 2013,8:249.DOI:10.1186/1748-717X-8-249. [31] Son SH,Choi BO,Ryu MR,et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma:dose-volumetric parameters predicting the hepatic complication[J].Int J Radiat Oncol Biol Phys,2010,78(4):1073-1080.DOI:10.1016/j.ijrobp.2009.09.009. [32] Mutter RW,Liu F,Abreu A,et al. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer[J].Int J Radiat Oncol Biol Phys,2012,82(5):1783-1790.DOI:10.1016/j.ijrobp.2011.03.053. [33] Dunlap NE,Cai J,Biedermann GB,et al. Chest wall volume receiving>30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy[J].Int J Radiat Oncol Biol Phys, 2010,76(3):796-801.DOI:10.1016/j.ijrobp.2009.02.027. [34] Marks LB,Yorke ED,Jackson A,et al. Use of normal tissue complication probability models in the clinic[J].Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S10-S19.DOI:10.1016/j.ijrobp.2009.07.1754. [35] Lo SS,Teh BS,Lu JJ,et al. Stereotactic body radiation therapy[M].Berlin Heidelberg:Springer-Verlag,2012:176.DOI:10.1007/978-3-642-25605-9.
2017, Vol. 26 
